Turn Therapeutics Inc.(TTRX)Earnings, Financials & Key Ratios

TTRX•NASDAQ

$9.71

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDrug Delivery Technology Platforms

AboutGlobal Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.Show more

Revenue$0
EBITDA-$6M-231.8%
Net Income-$3M-80.6%
EPS (Diluted)-0.23-76.9%
ROE-141.67%

TTRX Price & Volume

Turn Therapeutics Inc. (TTRX) stock price & volume — 10-year historical chart

Loading chart...

Pre-Revenue Liquidity Constraints Threaten Operational Sustainability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Pre-revenue liquidity exhaustion

Key Thesis Takeaways

Turn Therapeutics remains a high-risk, pre-commercial entity characterized by a total absence of revenue and a cost structure heavily skewed toward $2.1M in quarterly SG&A expenses.
The company's recent pivot toward debt financing, evidenced by a debt-to-equity ratio spike to 0.98 in 2026Q1, suggests an urgent need for capital to offset persistent operating losses.
Investors should monitor the firm's ability to achieve clinical milestones before the current $11.2M cash position is exhausted by ongoing operational burn.

Verdict Logic

the company's lack of revenue generation combined with a $1.6M quarterly free cash flow burn rate suggests significant dilution risk for shareholders.

TTRX Growth Metrics

Turn Therapeutics Inc. (TTRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-

Return on Capital

10 Years-144.39%

5 Years-144.39%

3 Years-144.39%

Last Year-156.24%

TTRX Recent Earnings

Turn Therapeutics Inc. (TTRX) EPS & revenue vs analyst estimates — last 3 quarters

Full history →

●Beat EPS 0/3 qtrs (0%)

Q2 2026Latest

May 11, 2026

Metric

Actual

Est

EPS

$0.03-50.0%

$0.02

Rev

—

Q2 2026

Mar 31, 2026

Metric

Actual

Est

EPS

$0.09-76.5%

$0.05

Rev

—

Q4 2025

Nov 13, 2025

Metric

Actual

Est

EPS

$0.07

—

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 11, 2026	$0.03vs $0.02-50.0%	—
Q2 2026	Mar 31, 2026	$0.09vs $0.05-76.5%	—
Q4 2025	Nov 13, 2025	$0.07	—

Based on last 3 quarters of dataView full earnings history →

Latest TTRX News

Recent stock market news and headlines for Turn Therapeutics Inc. (TTRX)

Business Wire·1 day ago

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the.

Peers Comparison

Key metrics vs top competitors for Turn Therapeutics Inc. (TTRX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
TTRXTurn Therapeutics Inc.Current	$9.71	$289.24M	-42.22	—	—	-141.67%	—
RCUSArcus Biosciences, Inc.	$30.25	$3.05B	-9.19	-4.26%	-156.36%	-68.97%	—
IMVTImmunovant, Inc.	$40.09	$8.23B	-14.47	—	—	-68.16%	—
ARQTArcutis Biotherapeutics, Inc.	$27.67	$3.46B	-212.85	91.34%	-0.57%	-1.41%	—
KYMRKymera Therapeutics, Inc.	$119.24	$9.74B	-32.31	-16.72%	-612.17%	-25.02%	—
PRAXPraxis Precision Medicines, Inc.	$323.95	$9.36B	-24.03	-100%	—	-43.02%	—

Compare TTRX vs Peers

Turn Therapeutics Inc. (TTRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RCUS

Most directly comparable listed peer for TTRX.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare TTRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs RCUS, IMVT, ARQT, KYMR

Get notified when TTRX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

TTRX Frequently Asked Questions

Turn Therapeutics Inc. (TTRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is TTRX profitable?

Turn Therapeutics Inc. (TTRX) reported a net loss of $3.8M for fiscal year 2025.

Dividend & Returns

What is TTRX's return on equity?

Turn Therapeutics Inc. (TTRX) has a return on equity (ROE) of -141.7%. Negative ROE indicates the company is unprofitable.

What is Turn Therapeutics Inc.'s free cash flow?

Turn Therapeutics Inc. (TTRX) had negative free cash flow of $3.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TTRX back in 2023?

Total return calculator · dividends reinvested · 3+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 11, 2026

$0.03vs $0.02-50.0%

—

Q2 2026

Mar 31, 2026

$0.09vs $0.05-76.5%

—

Q4 2025

Nov 13, 2025

$0.07

—

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

TTRXTurn Therapeutics Inc.Current

$9.71

$289.24M

-42.22

—

-141.67%

—

RCUSArcus Biosciences, Inc.

$30.25

$3.05B

-9.19

-4.26%

-156.36%

-68.97%

—

IMVTImmunovant, Inc.

$40.09

$8.23B

-14.47

—

-68.16%

—

ARQTArcutis Biotherapeutics, Inc.

$27.67

$3.46B

-212.85

91.34%

-0.57%

-1.41%

—

KYMRKymera Therapeutics, Inc.

$119.24

$9.74B

-32.31

-16.72%

-612.17%

-25.02%

—

PRAXPraxis Precision Medicines, Inc.

$323.95

$9.36B

-24.03

-100%

—

-43.02%

—